Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE versus QDOLO.
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a full mu-opioid receptor agonist, exerting analgesic and antitussive effects by binding to opioid receptors in the CNS and cough center. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
1 tablet (hydrocodone 5 mg/chlorpheniramine 4 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Hydrocodone: 3.8-8.5 hours (mean 5.3 hours); context: immediate-release, dosing intervals typically 4-6 hours. Chlorpheniramine: terminal half-life 12-43 hours (mean 21 hours); context: longer half-life supports twice-daily dosing, but effects may not correlate linearly.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Hydrocodone: primarily renal excretion as unchanged drug and conjugated metabolites (approx. 26% unchanged); minor biliary/fecal elimination. Chlorpheniramine: renal excretion of metabolites and unchanged drug (approx. 30% unchanged), with some fecal elimination.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist